ELL Antibody [B15J21] Datasheet

Biological Description

Specificity	ELL Antibody [B15J21] detects endogenous levels of total ELL protein.
Background	Eleven‑nineteen lysine‑rich leukemia protein (ELL) is an RNA polymerase II (Pol II) elongation factor that regulates transcriptional elongation kinetics and contributes to both general Pol II activity and gene‑specific activation programs. ELL interacts directly with the Pol II machinery and contains conserved domains that contact the elongating polymerase and link it to larger regulatory complexes such as the super elongation complex (SEC), where it associates with AFF family members, AF4/AF9/ENL, P‑TEFb, EAF1/2, and other SEC subunits to orchestrate the transition from promoter‑proximal pausing to productive elongation. ELL enhances the catalytic rate of Pol II by suppressing transient pausing and stabilizing early elongation complexes, and it participates in the establishment and clearance of pause sites genome‑wide, ensuring rapid and high‑amplitude transcriptional responses for inducible and developmentally regulated genes. ELL is incorporated into the SEC alongside MLL‑fusion partners, and chromosomal translocations that juxtapose the MLL gene with ELL generate oncogenic MLL–ELL fusions that recruit the SEC to MLL‑regulated loci such as HOX gene clusters, driving aberrant HOX expression and disrupting normal differentiation programs that underlie acute myeloid and lymphoid leukemias.

Specificity

ELL Antibody [B15J21] detects endogenous levels of total ELL protein.

Background

Eleven‑nineteen lysine‑rich leukemia protein (ELL) is an RNA polymerase II (Pol II) elongation factor that regulates transcriptional elongation kinetics and contributes to both general Pol II activity and gene‑specific activation programs. ELL interacts directly with the Pol II machinery and contains conserved domains that contact the elongating polymerase and link it to larger regulatory complexes such as the super elongation complex (SEC), where it associates with AFF family members, AF4/AF9/ENL, P‑TEFb, EAF1/2, and other SEC subunits to orchestrate the transition from promoter‑proximal pausing to productive elongation. ELL enhances the catalytic rate of Pol II by suppressing transient pausing and stabilizing early elongation complexes, and it participates in the establishment and clearance of pause sites genome‑wide, ensuring rapid and high‑amplitude transcriptional responses for inducible and developmentally regulated genes. ELL is incorporated into the SEC alongside MLL‑fusion partners, and chromosomal translocations that juxtapose the MLL gene with ELL generate oncogenic MLL–ELL fusions that recruit the SEC to MLL‑regulated loci such as HOX gene clusters, driving aberrant HOX expression and disrupting normal differentiation programs that underlie acute myeloid and lymphoid leukemias.

Usage Information

Application

WB, IP, IF, ChIP

Dilution

WB	IP	IF	CHIP
1:1000	1:100	1:1600	1:100

Reactivity

Human, Mouse, Rat

Source

Rabbit Monoclonal Antibody

MW

70 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/22252557/
https://pubmed.ncbi.nlm.nih.gov/9268387/

Application Data

WB

Validated by Selleck

Lane 1: 293T, Lane 2: 3T3, Lane 3: C2C12, Lane 4: H-4-II-E